anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a natural nonreactive moisturizing skin disinfectant. The natural nonreactive moisturizing skin disinfectant is prepared from 1-5% of chitosan, 10-30% of medical ethyl alcohol, 5-20% of artemisia apiacea extract, 5-30% of moringa oleifera leave extract, 0.5-5% of moringa oleifera seed oil and the balance deionized water. Chitosan is dissolved in moringa oleifera leave extract and artemisia apiacea extract to achieve bacterium resistance together with artemisia apiacea, moringa oleifera seeds and low-concentration ethyl alcohol, and sedimentation does not occur in low-concentration ethyl alcohol, so that the fungicidal effectiveness of the disinfectant is guaranteed. The disinfectant can kill staphylococcus, streptococcus, escherichia coli and other common pathogenic bacteria and common cold virus without adding antibiotics or other chemosynthetic antibiotic constituents. Moringa oleifera leaves and moringa oleifera seeds have remarkable skin care and skin moisturizing functions, and therefore the skin disinfectant can generate a moist feeling on skin and protect skin. The skin disinfectant has lasting and effective antibiosis and skin care effects, has no side effect on the human body, and does not cause pollution to the environment at all.
Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 \[course 5\], 17, 18 \[course 6\], 26, 27 \[course 9\], 29, and 30 \[course 10\] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Based on their multi-professional treatment plan in the Vanha Vaasa hospital, participation in the MCT group intervention is offered to patients who could benefit from it. The intervention under investigation is part of the standard care of the hospital. Participation does not prevent participation in other forms of rehabilitation, and patients can participate in the group even if they don't participate in the study. Being part of the control group does not prevent participation in the intervention group, but being part of the control group might delay participation. When these are in conflict, treatment takes precedence over research.

Data is collected until the sample size is satisfactory (at least 20 to 25 patients). Patients in the MCT condition are compared to patients (n=30) and controls (n=30) measured with a psychological test battery not completing the group. The test battery is the same for all the groups. It consists of valid tasks measuring neurocognition, social cognition, and psychiatric symptoms and a task for measuring the tendency to jump to conclusions. Patients in the group condition are tested before the group and nine months after the group has concluded. For both control groups testing interval is one year.

The comparison between the groups (intervention group, patient controls, and non-patient controls) is done by comparing the rate of change in the tendency to jump to conclusions. This comparison is done with regression analysis. If minor differences and equal variances are assumed (delta of slope 0.1), the power of the comparison is around 0.57. If larger differences are assumed (delta of slope 0.5), the power of the comparison approaches 1. In a previous study, a medium-sized comparative difference between patients in MCT condition and patients in cognitive remediation condition was found.

To avoid problems with multiple testing, the differences in magnitudes of mood symptoms, delusions, paranoia, and psychological flexibility after the delay are assessed with MANOVA. In a recent meta-analysis, the observed effect of MCT on delusions was high medium (g=0.69). The observed effect on negative symptoms was small but significant (g=0.23). Consequently, the expected power of the MANOVA ranges from 0.48 to 0.99. Direct comparisons are made with discriminant analysis with identical power estimates. Univariate ANOVAs can also be used, but with much worse power estimates, when controlling for multiple testing.
Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
We aimed to evaluate the effect of black soybean extract cream (BSEC) on 2,4-dinitrochlorobenzene (DNCB)-induced dermatitis in murine models mimicking inflammatory dermatitis observed in humans. In this DNCB-induced model, BALB/c mice were spread with 100 μL of 2% DNCB twice a week for two weeks to induce skin inflammation on the shaved back skin; then, a placebo or BSEC that consisted of the volatile fraction derived from the seeds of Glycine max (L.) Merr. was applied to the DNCB-sensitized mice for 7 days. Gross visual analysis was conducted to assess the impact of BSEC on dermatitis, and an enzyme-linked immunosorbent assay (ELISA) was subsequently performed to detect inflammatory cytokines in the presence or absence of BSEC after DNCB sensitization. Lastly, the possible mechanisms responsible for the effects of BSEC on inflammatory dermatitis were investigated in a human leukemia monocytic cell line, THP-1. Our study showed that BSEC displayed antioxidant and anti-inflammatory effects. BSEC has the ability to diminish dermatitis, and all three experiments demonstrated that BSEC effectively reduced the progression of dermatitis while significantly suppressing inflammatory responses in the preclinical models. Consequently, BSEC exhibited promising phytotherapy for inflammatory dermatitis, potentially attributed to its anti-inflammatory and antioxidant properties.
PURPOSE:To industrially and advantageously obtain a polysaccharide MA9 which is an antitumor agent, by extracting a tree bark of Melia azadirachta Linn. with water while boiling under pressure, adjusting the pH of the above- mentioned extract solution to a specific value and purifying the extract solution by an alcohol precipitation method. CONSTITUTION:A tree bark of Melia azadirachta Linn. is extracted with water while boiling, preferably 1-3atm (gauge pressure) pressure and the resultant extract solution is adjusted to 1-3pH. An alcohol is then added to collect the formed precipitates and afford the aimed polysaccharide MA9. Methanol or ethanol is preferably used as the alcohol. Purification by gel filtration is further required by a conventional method, but the polysaccharide MA9 is obtained in very high purity by an alcohol precipitation method in this method. Since the amount of the colored impurities is small, purification by the gel filtration is not required. The polysaccharide MA9 can be obtained in good yield in a short process and this method is suitable for industrial production.
Positive illusions and winning exposure are key factors leading to problem lottery gambling, but few studies have examined the relationships between them. 402 Chinese lottery gamblers was conducted with the Winning Exposure Questionnaire, the Positive illusion Questionnaire, the Winning Experience Questionnaire, and the Social and Economic Status Questionnaire to investigate the relationship between winning exposure and positive illusions as well as the moderating role of winning experience and socioeconomic status. The results showed that winning exposure can significantly and positively predict the positive illusions (optimism bias, better than average bias, and illusion of control) of lottery gamblers. The highest winning amount and subjective socioeconomic status significantly moderated the relationship between winning exposure and optimism bias. That was to say, for lottery gamblers with smaller maximum winning amount and lower subjective socioeconomic status, the association between winning exposure and optimism bias was stronger. Furthermore, the moderating effect of highest winning amount in the relationship between winning exposure and better than average bias, and the moderating effects of occupational status and subjective socioeconomic status in the relationship between winning exposure and illusion of control were marginally significant.
A system is disclosed in which a plurality of in-vitro diagnostic (IVD) devices each include a network communication device for connecting to a publicly accessible data network. For example, IVD devices are provided with a cellular modem for connecting to a public cellular network. These IVD devices connect to the data network upon completion of a diagnostic test, and upload results of the test, as well as other appropriate data, to a remote device which is also on the network. The IVD devices also download appropriate data from remote network elements. The remote network element may be a network element such as a Hospital Information System (HIS) or Laboratory Information System (LIS) database. Alternatively, the remote device may be a remote server or another IVD device. This connectivity enables the system to accumulate diagnostic test data, and to analyze, report, and/or update the IVD devices based on the accumulated data.
A total of 115 patients are planned to be enrolled in the study. Among them, AD group will enroll 10 cognitive normal controls, 15 prodromal Alzheimer's disease patients and 15 mild Alzheimer's disease patients. Non-AD group will enroll 15 patients with progressive supranuclear palsy (PSP) , 15 patients with frontotemporal dementia (FTD) carrying MAPT gene, 15 patients with FTD without MAPT gene (carrying other FTD related genes such as C9Orf, Progranulin, CHCHD10 or svPPA with TDP43 gene), 15 non-symptomatic carriers with MAPT mutation and 15 normal controls. Subjects who participated in cross-sectional validation study could also participate in this longitudinal study. Patients may also choose to participate only in the longitudinal study.
The invention relates to a medicine for treating asphyxia. The invention relates to the medicine, which is characterized in that the medicine is prepared by the following raw materials by weight portion: 25 to 35 portions of rhizoma arisaematis, 25 to 35 portions of tooth soap, 0.2 to 0.8 portion of storax, 0.2 to 0.8 portion of borneol, 1.5 to 4.5 portions of wrinkled gianthyssop, 8 to 12 portions of calculus bovis and 0.2 to 0.8 portion of cinnabar. Moreover, 8 to 12 portions of medical stones can also be added into the raw materials. When the medicine is manufactured, various raw materials are ground into fine powder on a stone mill and mixed, and then the finished medicine is obtained. 'Huichun capsules' manufactured by adoption of the method provided by the invention can be used for treating various asphyxias, hypertension and various pains, and have a simple method, small dosage, short treatment period, good effect and low cost, and patients are painless. The medicine is suitable for wide consumers, particularly low-income patients.
Techniques are provided for managing computing resources based on clinical priorities associated with one or more computing tasks. For example, one or more embodiments described herein may relate to a system. The system includes a memory that can store computer-executable components. The system may also include a processor operatively coupled to the memory, the processor executing computer-executable components stored in the memory. The computer-executable components may include a prioritization component that may prioritize computer applications based on a clinical priority of tasks performed by the computer applications. Clinical priorities may characterize the time sensitivity of these tasks. The computer-executable components may also include a resource pool component that may partition computing resources across multiple resource pools and may assign the computer applications to the multiple resource pools based on clinical priority.
OBJECTIVE: The Progressive Supranuclear Palsy quality of life scale (PSP-QoL) has been shown to be a useful tool for capturing health-related quality of life of patients in "everyday life" and in progressive supranuclear palsy (PSP) research. However, at 45 items in length, the questionnaire can take a long time, exhausting PSP patients, in particular if cognitive impaired, which can have a negative impact on the assessment. The aim of this study was to establish a condensed version of the PSP-QoL for research and routine clinical care.
METHODS: In this retrospective study, data originating from a German cohort of PSP patients was analyzed. Data from 245 PSP patients were included in this study. The short PSP-QoL questionnaire was created using a two-factor solution and item-total and inter-item correlations for mental and physical aspects of daily living of the PSP-QoL followed by confirmatory factor analysis.
RESULTS: The final scale included 12 items representing mental (five items) and physical symptoms (seven items). The specified two-factor model displayed an excellent fit in the confirmatory factor analysis. The short Progressive Supranuclear Palsy Quality of Life scale (PSP-ShoQoL) correlated moderately with the PSP Rating Scale (r [243] = 0.514, P < 0.001) and Geriatric depression scale (r [231] = 0.548, P < 0.001). Sensitivity to change confirmed a significant decrease in QoL after 12 months.
DISCUSSION: In this study, we created a 12-item PSP-ShoQoL designed to "facilitate" daily clinical work that correlated strongly with the PSP-QoL and was sensitive to change. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Retrospective evaluation of data from 2 years prior to the implementation of our CRRT KPI reports. This will include approximately 1500 participants.
Despite its global importance as a primary source of table sugar and bioethanol, sugarcane faces a significant threat to its production due to diseases. One of these diseases, sugarcane smut, involves the emergence of a whip-like structure from the host apical shoot. The slow onset of this pathogenesis is the most substantial challenge for researchers to investigate the molecular events leading to resistance or susceptibility. In this study, we explored the early interaction between the smut fungus Sporisorium scitamineum and foliar tissues of the model plants Arabidopsis thaliana and Nicotiana benthamiana. Upon inoculation with the fungus, A. thaliana showed a compatible reaction, producing lesions during fungus colonization, whereas N. benthamiana showed signs of nonhost resistance. In addition, we propose a sugarcane detached leaf assay using plants cultivated in vitro to reveal sugarcane smut response outcomes. We used two sugarcane genotypes with known contrasting reactions to smut in the field. Although there is no evidence of sugarcane smut fungus infecting host leaves naturally, the sugarcane detached leaf assay enabled a rapid assessment of disease outcomes. Different symptoms in the detached leaves after inoculation distinguished smut-susceptible and smut-resistant sugarcane genotypes. Microscopic observations and gene expression analysis of S. scitamineum candidate effectors confirmed the fungal growth and its restriction on the compatible and incompatible interactions, respectively. These findings offer new prospects into the disease phenotyping of S. scitamineum, which could greatly expedite the comprehension of the initial stages of the pathogenesis and predict smut resistance in sugarcane genotypes.
OBJECTIVES: The threshold to perform concomitant tricuspid valve (TV) repair during primary mitral valve (MV) surgery has decreased, based on recent randomized evidence. Based on these developments, the indication for TV repair during MV surgery is expected to increase further. However, concerns have been raised regarding the risk of permanent pacemaker implantation (PPI) during a concomitant procedure. Therefore, we aim to assess the incidence of PPI in combined MV and TV surgery in a nationwide registry.
METHODS: The current study uniquely cross-linked the Cardiothoracic and Pacemaker/ICD registry of the Netherlands Heart Registration. Patients undergoing primary MV and TV surgery (± atrial septal defect closure, rhythm surgery, coronary artery bypass grafting) between 1 January and 31 December2021 were included. The primary outcome was PPI within 30 days after surgery. Subgroup analyses were performed for isolated MV and TV surgery and MV repair. The association between concomitant TV surgery and PPI was assessed using multivariable binary logistic regression analyses.
RESULTS: A total of 1060 patients (n = 833 MV, n = 227 MV + TV) were included. The overall incidence of PPI was 4.3%. No significant difference in PPI between MV and MV + TV surgery were found (3.7% vs 6.6%, P = 0.06). Concomitant TV surgery was not an independent risk factor for PPI after surgery after adjustment for covariates. These results were robust after sensitivity analyses.
CONCLUSIONS: The current study was not able to find a statistical difference between the PPI rate in MV surgery patients and MV + TV surgery patients. Extension of the waiting period prior to PPI, may result in decreased PPI rates.
Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
The FLEXX trial was the first well-controlled, randomized, double-blind, multicenter study evaluating the efficacy of Euflexxa (1% sodium hyaluronate) therapy for knee osteoarthritis. Five-hundred-and-eighty patients were randomized to receive either Euflexxa or normal saline. There were significant improvements in the Visual analogue scale score Osteoarthritis Research Society International responder index, HRQoL, and function at 26-week follow-up.1 However, the FLEXX trial did not evaluate changes in synovial fluid bio-marker levels. The present study will be a prospective pilot study of 30 knees from subjects who receive intra-articular Euflexxa. The primary objective of this study is to prospectively determine, at 6-weeks, and 6-months post treatment, the changes in levels of synovial fluid biomarkers from pre- to post-injection in patients who receive Euflexxa. In addition, we will assess patient reported pain and patient reported outcomes up to 2 years from initiation of study.
Despite widespread use of statin therapy for reducing risk of cardiovascular disease risk, there is considerable inter-individual variation in statin efficacy, and it would be desirable to identify markers that would be predictive of the magnitude of beneficial response. The effect of statin most strongly associated with improved clinical outcomes is reduction in LDL cholesterol. The CAP study was a six week non-randomized, open label study of simvastatin 40 mg/day in a group of 335 African-American and 609 Caucasian volunteer subjects. Measurements of plasma lipids and lipoproteins, as well as other markers of cardiovascular disease risk, were obtained at the screening and entry visits, and after four and six weeks of simvastatin treatment. Both baseline measurements and changes in response to simvastatin therapy are being used to test for associations with genetic polymorphisms. Significant findings are being replicated in other study cohorts.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to derivatives of tetrahydroisoquinoline alkanol of the formula (I)   wherein X 1  and X 2  are hydrogen, halogen atom, alkoxy-group or nitro-group; Y is oxygen or sulfur atom; R 1  is hydrogen atom, alkyl, phenylalkyl or CONHR' wherein R' is phenyl; R 2  and R 3  are similar or different of one another and are taken independently among group consisting of hydrogen atom and alkyl; R 4  is hydrogen atom or lower alkyl. Also, invention describes pharmaceutical composition and methods for treatment of central nervous system disorders and depression. Invention provides preparing new compounds eliciting valuable biological properties. EFFECT: improved treatment method, valuable medicinal properties of compounds. 55 cl, 1 tbl, 22 ex
Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. CPA will be self-administered 50 mg BID for 7 days on and 7 days off starting on D0.
BACKGROUND: The immediate impact of catheter ablation on left atrial mechanical function and the timeline for its recovery in patients undergoing ablation for atrial fibrillation (AF) remain uncertain. The mechanical function response to catheter ablation in patients with different AF types is poorly understood.
METHODS: A total of 113 AF patients were included in this retrospective study. Each patient had three magnetic resonance imaging (MRI) studies in sinus rhythm: one pre-ablation, one immediate post-ablation (within 2 days after ablation), and one post-ablation follow-up MRI (≤ 3 months). We used feature tracking in the MRI cine images to determine peak longitudinal atrial strain (PLAS). We evaluated the change in strain from pre-ablation, immediately after ablation to post-ablation follow-up in a short-term study (< 50 days) and a 3-month study (3 months after ablation).
RESULTS: The PLAS exhibited a notable reduction immediately after ablation, compared to both pre-ablation levels and those observed in follow-up studies conducted at short-term (11.1 ± 9.0 days) and 3-month (69.6 ± 39.6 days) intervals. However, there was no difference between follow-up and pre-ablation PLAS. The PLAS returned to 95% pre-ablation level within 10 days. Paroxysmal AF patients had significantly higher pre-ablation PLAS than persistent AF patients in pre-ablation MRIs. Both type AF patients had significantly lower immediate post-ablation PLAS compared with pre-ablation and post-ablation PLAS.
CONCLUSION: The present study suggested a significant drop in PLAS immediately after ablation. Left atrial mechanical function recovered within 10 days after ablation. The drop in PLAS did not show a substantial difference between paroxysmal and persistent AF patients.
<P>PROBLEM TO BE SOLVED: To provide a summer heat stress alleviating composition and a food or beverage containing the composition which can be continuously taken in by preference even at the time of oppressive heat (for example, in the summer in Japan) when the appetite and the will of action diminish.  <P>SOLUTION: The summer heat stress alleviating composition comprises at least lees of rice wine and rice bran. This summer heat stress alleviating composition is preferably used in inhibiting the loss of appetite due to the summer heat stress and/or the lowering of the amount of spontaneous behavior due to the summer heat stress. Further, this summer heat stress alleviating composition can be composed of a sweet drink made from fermented rice which contains at least lees of rice wine and rice bran. With the use of the summer heat stress alleviating composition, a food or beverage making good use of the flavor can be obtained.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.